## IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF VIRGINIA ABINGDON DIVISION

UNITED STATES OF AMERICA	)
v.	) Dkt. No
THE PURDUE FREDERICK COMPANY, INC	) C.)
D/B/A The Purdue Frederick Company	)
MICHAEL FRIEDMAN	)
HOWARD R. UDELL	)
PAUL D. GOLDENHEIM	)

### **AGREED STATEMENT OF FACTS**

### Introduction

- 1. Defendant The PURDUE FREDERICK COMPANY, INC. (referred to in this Agreed Statement of Facts as "PURDUE"), doing business as The Purdue Frederick Company, was a New York corporation, headquartered in Connecticut. It was created in 1892 and was purchased by its current owners in 1952. At all times relevant to this Agreed Statement of Facts, PURDUE and other related and associated entities were engaged in the pharmaceutical business throughout the United States.
- 2. PURDUE developed and originally marketed OxyContin Tablets ("OxyContin"), an opioid analgesic approved to be taken every twelve hours. OxyContin is a controlled-release form of oxycodone and is a Schedule II controlled substance with an abuse liability similar to morphine.
- 3. Defendant MICHAEL FRIEDMAN joined PURDUE in 1985 as Vice President and Assistant to the President and Chairman. He was appointed Group Vice President in 1988, Executive Vice President and Chief Operating Officer in 1999, and President and Chief Executive Officer in 2003.

Attachment B to Plea Agreement United States v. The Purdue Frederick Co., Inc.

Page 1 of 16

- 4. Defendant HOWARD R. UDELL joined PURDUE in 1977 as General Counsel. He was appointed Group Vice President and General Counsel in 1989, Executive Vice President and General Counsel in 1999, and Executive Vice President and Chief Legal Officer in 2003.
- 5. Defendant PAUL D. GOLDENHEIM joined PURDUE in 1985 as Medical Director. He was appointed Vice President and Medical Director in 1986, Vice President of Scientific and Medical Affairs and Executive Director of Purdue Frederick Research Center in 1988, Group Vice President of Scientific and Medical Affairs in 1989, Executive Vice President of Medical and Scientific Affairs in 1999, Executive Vice President of Worldwide Research & Development in 2000, and Executive Vice President of Worldwide Research & Development and Chief Scientific Officer in 2003. He left PURDUE in 2004.
- 6. From January 1996 through June 30, 2001, PURDUE received approximately \$2.8 billion in revenue from the sale of OxyContin.

#### Statutory Framework

- 7. The United States Food and Drug Administration ("FDA") is the agency of the United States responsible for protecting the public health by ensuring the safety, efficacy, and security of human drugs and for enforcing the Federal Food, Drug, and Cosmetic Act ("FDCA"), 21 U.S.C. §§ 301, et seq.
- 8. The FDCA, 21 U.S.C. § 355, required a sponsor of a new drug to receive FDA approval of a New Drug Application ("NDA"), before the sponsor could distribute the drug in interstate commerce.
- 9. The FDCA, 21 U.S.C. § 321(m), defined labeling to include "all labels and other written, printed, or graphic matter . . . accompanying [a drug]." Title 21, Code of Federal

Attachment B to Plea Agreement United States v. The Purdue Frederick Co., Inc.

Page 2 of 16

Regulations, Section 202.1(1)(2) provided that labeling included brochures, booklets, mailing

pieces, detailing pieces, bulletins, letters, motion picture films, sound recordings, exhibits, literature,

and reprints and similar pieces of printed, audio, or visual matter descriptive of a drug which were

disseminated by or on behalf of a drug's manufacturer, packer, or distributor. Such items

"accompanied" a drug if they were designed for use and used in the distribution and sale of the drug.

10. The FDCA, 21 U.S.C. § 352(a), provided that a drug was misbranded "[i]f its labeling

[was] false or misleading in any particular." The FDCA, 21 U.S.C. § 321(n), provided that "[i]n

determining whether the labeling . . . [was] misleading there shall be taken into account (among

other things) not only representations made or suggested by statement, word, design, device, or any

combination thereof, but also the extent to which the labeling fails to reveal facts material in the

light of such representation or material with respect to the consequences which may result from the

use . . . to which the labeling . . . relates under the conditions of use prescribed in the labeling . . .

or under such conditions of use as are customary or usual."

11. The FDCA, 21 U.S.C. § 331(a), prohibited the introduction or delivery for

introduction into interstate commerce of a misbranded drug. 21 U.S.C. § 333(a)(2) provided that

such a violation committed with the intent to defraud or mislead was punishable as a felony. Under

21 U.S.C. § 333(a)(1) and the applicable case law, an individual could be held criminally liable for

a misdemeanor violation of § 331(a) without having knowledge of, or intent to cause, the

misbranding if that individual was a responsible corporate officer at the time of the misbranding.

A responsible corporate officer for these purposes was one who had responsibility and authority

either to prevent in the first instance or to promptly correct certain conduct resulting in the

misbranding of a drug introduced or delivered for introduction into interstate commerce.

Attachment B to Plea Agreement United States v. The Purdue Frederick Co., Inc.

Page 3 of 16

12. OxyContin was a drug within the meaning of the FDCA, 21 U.S.C. § 321(g)(1), and a new drug within the meaning of 21 U.S.C. § 321(p).

### OxyContin Approval and Package Insert

- 13. On approximately December 28, 1994, PURDUE submitted the OxyContin NDA to the FDA. The NDA included clinical studies showing that OxyContin, when dosed every twelve hours, was as safe and as effective as immediate-release oxycodone dosed every six hours.
- 14. The NDA did not claim that OxyContin was safer or more effective than immediate-release oxycodone or other pain medications and PURDUE did not have, and did not provide the FDA with, any clinical studies demonstrating that OxyContin was less addictive, less subject to abuse and diversion, or less likely to cause tolerance and withdrawal than other pain medications.
- 15. On or about October 24, 1995, the FDA completed, with PURDUE's assistance, an internal Medical Officer Review ("MOR") of the Integrated Summary of Safety ("ISS") and a MOR of the Integrated Summary of Efficacy ("ISE"). While not binding on the company, the MORs were disclosed to certain PURDUE supervisors and employees. These MORs did not state that OxyContin was more effective than or superior to, safer, had less opioid effects, or caused fewer adverse events than any other marketed product.
  - 16. The MOR of the ISS included these statements:
  - a. "The blood level data in clinical use suggests the opioid effects [of OxyContin and immediate-release oxycodone] would be similar;"
  - b. "The best conclusion is that the efficacy of [OxyContin] is equivalent to the [immediate-release oxycodone], with an adverse event profile that is as good as the [immediate-release oxycodone]. <u>I would not allow a 'better' claim</u>." (emphasis in original);
  - c. "The adverse experience profile of [OxyContin] is qualitatively similar to that of the parent drug, oxycodone;" and

Attachment B to Plea Agreement United States v. The Purdue Frederick Co., Inc. d. "Withdrawal is possible in patients who have their dosage abruptly reduced or discontinued."

#### 17. The MOR of the ISE included these statements:

- a. "There is <u>some</u> evidence, both pharmacokinetic and clinical, that reduced acute opioid adverse effects may be expected in some patients, but there is not enough evidence to support an [adverse event] superiority claim [for OxyContin] against other marketed products." (emphasis in original); and
- b. "Care should be taken to limit competitive promotion. [OxyContin] has been shown to be as good as current therapy, but has not been shown to have a significant advantage beyond reduction in frequency of dosing."
- 18. The FDA approved the OxyContin NDA on December 12, 1995, and from 1996 through June 30, 2001, the FDA-approved package insert for OxyContin stated that it was intended for "the management of moderate to severe pain where use of an opioid analgesic is appropriate for more than a few days." The package insert also included the statement: "Delayed absorption, as provided by OxyContin tablets, is believed to reduce the abuse liability of a drug."

## Misbranding of OxyContin

- 19. During the period February through March 1995, PURDUE supervisors and employees obtained market research that included focus groups of forty primary care physicians, rheumatologists, and surgeons to determine their receptivity to using OxyContin for non-cancer pain. According to this market research, some of these physicians had concerns, similar to their concerns about combination opioids, regarding OxyContin's addictive potential and side effect profile, including that "[t]he biggest negative of [OxyContin] was the abuse potential."
- 20. Beginning on or about December 12, 1995, and continuing until on or about June 30, 2001, certain PURDUE supervisors and employees, with the intent to defraud or mislead, marketed and promoted OxyContin as less addictive, less subject to abuse and diversion, and less likely to

Attachment B to Plea Agreement United States v. The Purdue Frederick Co., Inc.

Page 5 of 16

cause tolerance and withdrawal than other pain medications, as follows:

a. Trained PURDUE sales representatives and told some health care providers that

it was more difficult to extract the oxycodone from an OxyContin tablet for the purpose of

intravenous abuse, although PURDUE's own study showed that a drug abuser could extract

approximately 68% of the oxycodone from a single 10 mg OxyContin tablet by crushing the

tablet, stirring it in water, and drawing the solution through cotton into a syringe;

b. Told PURDUE sales representatives they could tell health care providers that

OxyContin potentially creates less chance for addiction than immediate-release opioids;

c. Sponsored training that taught PURDUE sales supervisors that OxyContin had

fewer "peak and trough" blood level effects than immediate-release opioids resulting in less

euphoria and less potential for abuse than short-acting opioids;

d. Told certain health care providers that patients could stop therapy abruptly

without experiencing withdrawal symptoms and that patients who took OxyContin would

not develop tolerance to the drug; and

e. Told certain health care providers that OxyContin did not cause a "buzz" or

euphoria, caused less euphoria, had less addiction potential, had less abuse potential, was

less likely to be diverted than immediate-release opioids, and could be used to "weed out"

addicts and drug seekers.

Misbranding of OxyContin: Use of Graphical Depictions by Sales Representatives

21. Data from one of PURDUE's clinical studies was used to create the following


graphical demonstration of the difference in the plasma levels at steady state between patients who

took OxyContin every twelve hours (the "10 mg CR" line) and patients who took immediate-release


Attachment B to Plea Agreement United States v. The Purdue Frederick Co., Inc.

Page 6 of 16

oxycodone every six hours (the "5 mg IR" line):




22. On October 12, 1995, PURDUE requested comments from the FDA's Division of Drug Marketing, Advertising, and Communication ("DDMAC") about its proposed launch marketing materials, which included the following graph and text showing the oxycodone plasma concentration provided by OxyContin on a logarithmic scale along with the statement that OxyContin's oxycodone blood plasma levels provided "fewer 'peaks and valleys' than with immediate-release oxycodone:"



Attachment B to Plea Agreement United States v. The Purdue Frederick Co., Inc.

Page 7 of 16

- 23. On or about December 20, 1995, after reviewing the proposed OxyContin launch materials, DDMAC informed PURDUE that "[i]f [Purdue] wishes to compare blood levels in the text, then DDMAC suggests that the blood levels for both dosage forms be presented in the graphic so that the reader can accurately interpret this claim."
- 24. On or about January 11, 1996, PURDUE told DDMAC that it had "deleted" the statement "[f]ewer peaks and valleys than with immediate-release oxycodone."
- 25. In or about December 1998, PURDUE sponsored training for all of its district sales managers. During this meeting, a pharmacist retained by PURDUE to conduct a portion of the training used the following graphical demonstration (instead of the graphical demonstration of the actual clinical data described in paragraph 21 of this Agreed Statement of Facts), and falsely stated that OxyContin had significantly fewer "peak and trough" blood level effects than immediate-release opioids resulting in less euphoria and less potential for abuse than short-acting opioids:



Attachment B to Plea Agreement United States v. The Purdue Frederick Co., Inc.

Page 8 of 16

26. Beginning in or around 1999, some of PURDUE's new sales representatives were

permitted, during training at PURDUE's headquarters, to draw their own blood level graphs to falsely

represent that OxyContin, unlike immediate-release or short-acting opioids, did not swing up and

down between euphoria and pain, and resulted in less abuse potential.

27. During the period 1999 through June 30, 2001, certain PURDUE sales representatives

used graphical depictions similar to the one described in paragraph 25 of this Agreed Statement of

Facts and falsely stated to some health care providers that OxyContin had less euphoric effect and

less abuse potential than short-acting opioids.

Misbranding of OxyContin: Misleading Use of Article to Claim No Withdrawal or Tolerance

28. On or about January 16, 1997, certain PURDUE supervisors and employees sent to

the FDA the results of a clinical study pertaining to the use of low doses of OxyContin by

osteoarthritis patients ("osteoarthritis study") and a final study report that included, in a section

pertaining to respite periods, the statement "[n]o investigator reported 'withdrawal syndrome' as an

adverse experience during the respite periods." In a section entitled "Adverse Experiences by Body

System During Respite Periods," the report's summary of the major results listed the most frequently

reported adverse experiences in respite periods to be nervousness, insomnia, nausea, pain, anxiety,

depression, and diarrhea, followed by the statement: "Twenty-eight patients (26%) had symptoms

recorded during 1 or more respite periods."

29. In or about May 1997, certain PURDUE supervisors and employees stated that while

they were well aware of the incorrect view held by many physicians that oxycodone was weaker than

morphine, they did not want to do anything "to make physicians think that oxycodone was stronger

or equal to morphine" or to "take any steps in the form of promotional materials, symposia, clinicals,

Attachment B to Plea Agreement United States v. The Purdue Frederick Co., Inc.

Page 9 of 16

publications, conventions, or communications with the field force that would affect the unique position that OxyContin ha[d] in many physicians mind (sic)."

30. On or about February 12, 1999, certain supervisors and employees of a United Kingdom company affiliated with PURDUE provided certain PURDUE supervisors and employees with an analysis of the osteoarthritis study together with another clinical study. This analysis included a list of eight patients in the osteoarthritis study and eleven patients in the other study "who had symptoms recorded that may possibly have been related to opioid withdrawal," including one patient in the other study who required treatment for withdrawal syndrome. The "Discussion" section of this analysis included the following: "It is not surprising that some patients in the clinical trials developed some degree of physical dependence and consequently experienced withdrawal symptoms as a result of abrupt discontinuation of OxyContin tablets. All patients who were suspected to have withdrawal symptoms have been reported but this may have resulted in a falsely high incidence. Of the patients who participated in [the osteoarthritis study] (in which patients entered respite periods without OxyContin tablets) many symptoms suspected to be due to opioid withdrawal may simply have resulted from the return of pain. After withdrawal of OxyContin tablets, patient 6007 complained of nervousness, patient 2004 complained of insomnia and felt restless and patients 2020 and 2028 were restless and anxious. Since these are symptoms which often accompany the return of significant pain, it may be wrong to label these as withdrawal symptoms. Nonetheless, the incidence of withdrawal syndromes in patients treated with OxyContin tablets is a concern and it is safer to over report, than under report this potential problem." The analysis' conclusions included the statement: "As expected, some patients did become physically dependent on OxyContin tablets but this is not expected to be a clinical problem so long as abrupt withdrawal of drug is avoided."

Attachment B to Plea Agreement United States v. The Purdue Frederick Co., Inc.

Page 10 of 16

31. Certain PURDUE supervisors and employees participated in the drafting of an article

regarding the osteoarthritis study that was published in a medical journal on or about March 27, 2000

("osteoarthritis study article"). The "Results" section of the article included the following three

statements pertaining to the incidence of withdrawal syndrome and withdrawal symptoms

experienced by study patients: (1) One patient was hospitalized "for withdrawal symptoms . . . . The

patient who was hospitalized with withdrawal symptoms had completed the study on the previous

day and had been receiving CR oxycodone, 70 mg/d; symptoms resolved after 3 days." (2) "A second

patient, who was receiving 60 mg/d CR oxycodone, experienced withdrawal symptoms after running

out of study medication. The patient had not reported withdrawal symptoms during scheduled

respites from doses of 30 or 40 mg/d." (3) "Withdrawal syndrome was not reported as an adverse

event for any patient during scheduled respites. Adverse experiences reported by more than 10% of

patients during scheduled respites were nervousness (9 patients) and insomnia (8 patients)."

32. The osteoarthritis study article also included a "Comment" section. The statement

regarding withdrawal in this section largely summarized the information in the three statements in

the "Results" section and further suggested that patients taking low doses could have their OxyContin

treatment abruptly discontinued without experiencing withdrawal if their condition so warranted:

"There were 2 reports of withdrawal symptoms after patients abruptly stopped taking CR oxycodone

at doses of 60 or 70 mg/d. Withdrawal syndrome was not reported as an adverse event during

scheduled respites, indicating that [OxyContin] at doses below 60 mg [per day] can be discontinued

without tapering the dose if the patient's condition so warrants."

33. On or about May 18, 2000, after millions of OxyContin tablets had been sold and used

by patients, PURDUE's Medical Services Department reported to certain PURDUE supervisors and

employees that it had recently received a report of a patient who said he or she was unable to stop

taking OxyContin 10 mg every 12 hours without experiencing withdrawal symptoms and the report

indicated that "this type of question, patients not being able to stop OxyContin without withdrawal

symptoms has come up quite a bit here in Medical Services lately (at least 3 calls in the last 2 days)."

34. On or about June 26, 2000, certain PURDUE supervisors and employees sent the full

text of the osteoarthritis study article together with a "marketing tip" to PURDUE's entire sales force.

The marketing tip stated that a reprint of the osteoarthritis study article was available for use in

achieving sales success. The marketing tip also included as one of the article's twelve key points:

"There were 2 reports of withdrawal symptoms after patients abruptly stopped taking CR oxycodone

at doses of 60 or 70 mg/d. Withdrawal syndrome was not reported as an adverse event during

scheduled respites indicating that CR oxycodone at doses below 60 mg/d can be discontinued without

tapering the dose if the patient condition so warrants."

35. On or about February 13, 2001, certain PURDUE supervisors and employees received

a review of the accuracy of the withdrawal data in the osteoarthritis study that stated: "Upon a review

of all comments for all enrolled patients, it was noted that multiple had comments which directly

stated or implied that an adverse experience was due to possible withdrawal symptoms." This was

followed by a list of eleven study patients who reported adverse experience due to possible

withdrawal symptoms during these periods. 106 patients initially participated in the osteoarthritis

study, 32 of them withdrew because of adverse events (not necessarily related to withdrawal), and

38 patients remained in the study at 12 months.

36. On or about March 28, 2001, a PURDUE employee emailed a PURDUE supervisor

regarding the review of withdrawal data described in paragraph 35 of this Agreed Statement of Facts,

Attachment B to Plea Agreement
United States v. The Purdue Frederick Co., Inc.

Page 12 of 16

asking: "Do you think the withdrawal data from the [osteoarthritis] study . . . is worth writing up (an abstract)? Or would this add to the current negative press and should be deferred?" The supervisor

responded: "I would not write it up at this point." No abstract was prepared.

37. Between approximately June 26, 2000, and June 30, 2001, certain PURDUE

supervisors and employees distributed copies of the reprint of the osteoarthritis study article to all of

PURDUE's sales representatives for use in the promotion and marketing of OxyContin to health care

providers, including the distribution of 10,615 copies to certain PURDUE sales representatives

between February 13, 2001, and June 30, 2001.

38. During the period June 26, 2000, through June 30, 2001, certain PURDUE sales

representatives distributed the reprint of the osteoarthritis study article to some health care providers

and falsely or misleadingly stated that patients taking OxyContin at doses below 60 milligrams per

day can always be discontinued abruptly without withdrawal symptoms and that patients on such

doses would not develop tolerance.

Misbranding of OxyContin: Use of Reduced Abuse Liability Claim in Marketing

39. The original OxyContin package insert approved by the FDA stated: "Delayed

absorption, as provided by OxyContin tablets, is believed to reduce the abuse liability of a drug" (the

Reduced Abuse Liability Statement). Certain PURDUE supervisors and employees instructed

PURDUE sales representatives to use this statement to market and promote OxyContin.

40. Certain PURDUE sales representatives, while promoting and marketing OxyContin,

falsely told some health care providers that the Reduced Abuse Liability Statement meant that

OxyContin did not cause a "buzz" or euphoria, caused less euphoria, had less addiction potential, had

less abuse potential, was less likely to be diverted than immediate-release opioids, and could be used

Attachment B to Plea Agreement United States v. The Purdue Frederick Co., Inc.

Page 13 of 16

to "weed out" addicts and drug seekers.

41. By March 2000, various PURDUE supervisors and employees in different parts of the

company had received reports of OxyContin abuse and diversion occurring in different communities.

42. On or about November 27, 2000, certain PURDUE supervisors and employees

amended the Reduced Abuse Liability Statement to state that "[d]elayed absorption, as provided by

OxyContin tablets, when used properly for the management of pain, is believed to reduce the abuse

liability of a drug," and instructed PURDUE sales representatives to use the amended statement to

promote and market OxyContin.

43. From March 2000 through June 30, 2001, certain PURDUE sales representatives,

while promoting and marketing OxyContin, falsely told some health care providers that the Reduced

Abuse Liability Statement and the amended statement meant that OxyContin did not cause a "buzz"

or euphoria, caused less euphoria, had less addiction potential, had less abuse potential, was less

likely to be diverted than immediate-release opioids, and could be used to "weed out" addicts and

drug seekers.

Introduction of Misbranded OxyContin Into Interstate Commerce

44. In or about and between January 1996 and June 30, 2001, PURDUE manufactured,

marketed, and sold quantities of OxyContin in interstate commerce from various locations outside

the state of Virginia to various locations in the Western District of Virginia and elsewhere, which

were misbranded within the meaning of 21 U.S.C. §§ 331(a), 333(a)(2), and 352(a), as described in

paragraphs 19 through 43 of this Agreed Statement of Facts.

45. Between in or about January 1996 and on or about June 30, 2001, defendants

MICHAEL FRIEDMAN, HOWARD R. UDELL, and PAUL D. GOLDENHEIM, were responsible

Attachment B to Plea Agreement
United States v. The Purdue Frederick Co., Inc.

Page 14 of 16

corporate officers of PURDUE under 21 U.S.C. §§ 331(a), 333(a)(1), and 352(a).

46. Defendants MICHAEL FRIEDMAN, HOWARD R. UDELL, and PAUL D. GOLDENHEIM ("individual defendants") do not agree that they had personal knowledge of all of the matters set forth in paragraphs 1 through 44 of this Agreed Statement of Facts. However, they agree that the Court may accept these facts, as agreed to by defendant THE PURDUE FREDERICK COMPANY, INC., as part of the factual basis supporting the guilty pleas by the individual defendants.

The parties agree to the foregoing Agreed Statement of Facts.

Date: May 9, 2007

FOR THE UNITED STATES:

John L. Brownlee United States Attorney Western District of Virginia

Rick A. Mountcastle, Assistant United States Attorney Randy Ramseyer, Assistant United States Attorney Sharon Burnham, Assistant United States Attorney Barbara T. Wells, Trial Attorney, U.S. Dept. Of Justice Elizabeth Stein, Trial Attorney, U.S. Dept. Of Justice

Brounlee

Date: May 7, 2007	Robin E. Abrams, Esquire Vice-President and Director of The Purdue Frederick Company, Inc. and Vice-President and Associate General Counse of Purdue Pharma L.P.
Date: May 8, 2007	Authorized Corporate Officer for  The Purque Frederick Company, Inc.  Howard M. Shapiro, Esquire  Counsel for The Purdue Frederick Company, Inc.
Date: May 7, 2007  Date:	FOR DEFENDANT MICHAEL FRIEDMAN:  Michael Friedman, Defendant
	Mark D. Pomerantz, Esquire Counsel for Michael Friedman
Date: May 7, 2007  Date:	FOR DEFENDANT HOWARD R. UDELL:  Howard R. Udell, Defendant
Date.	Mary Jo White, Esquire Counsel for Howard R. Udell
Data	FOR DEFENDANT PAUL D. GOLDENHEIM:
Date:	Paul D. Goldenheim, Defendant
	Andrew Good, Esquire Counsel for Paul D. Goldenheim

# FOR DEFENDANT THE PURDUE FREDERICK COMPANY, INC.:

Date:	
	Robin E. Abrams, Esquire
	Vice-President and Director of
	The Purdue Frederick Company, Inc. and
	Vice-President and Associate General Counse
	of Purdue Pharma L.P.
	Authorized Corporate Officer for
	The Purdue Frederick Company, Inc.
D .	
Date:	Harrand M. Chamina, Enguina
	Howard M. Shapiro, Esquire
	Counsel for The Purdue Frederick Company, Inc.
,	FOR DEFENDANT MICHAEL FRIEDMAN:
Date: $\frac{5/7/07}{6}$	1.41110
Date:	Michael Friedman, Defendant
11.1.1	21 De A
Date: 5/8/07	Mark & tomes
•	Mark P. Pomerantz, Esquire
	Counsel for Michael Friedman
	FOR DEFENDANT HOWARD R. UDELL:
Date:	
	Howard R. Udell, Defendant
Date:	
	Mary Jo White, Esquire
	Counsel for Howard R. Udell
	FOR DEFENDANT PAUL D. GOLDENHEIM:
Date:	
	Paul D. Goldenheim, Defendant
Date:	
	Andrew Good, Esquire
	Counsel for Paul D. Goldenheim

# FOR DEFENDANT THE PURDUE FREDERICK COMPANY, INC.:

Date:	
	Robin E. Abrams, Esquire
	Vice-President and Director of
	The Purdue Frederick Company, Inc. and
	Vice-President and Associate General Counsel
	of Purdue Pharma L.P.
	Authorized Corporate Officer for
	The Purdue Frederick Company, Inc.
Date:	
	Howard M. Shapiro, Esquire
	Counsel for The Purdue Frederick Company, Inc.
	FOR DEFENDANT MICHAEL FRIEDMAN:
Date:	
	Michael Friedman, Defendant
Date:	
	Mark D. Pomerantz, Esquire
	Counsel for Michael Friedman
Date: 5/7/01	FOR DEFENDANT HOWARD R. UDELL:
	Howard R. Udell, Defendant
Date: $\frac{5/7/07}{5/8/07}$	_ Mary for White/ye
Pate.	Mary Jo White, Esquire
	Counsel for Howard R. Udell
	FOR DEFENDANT PAUL D. GOLDENHEIM:
Date:	
n .	Paul D. Goldenheim, Defendant
Date:	Andrew Good, Esquire
	Counsel for Paul D. Goldenheim
	Counsel for Faul D. Goldenheim

# FOR DEFENDANT THE PURDUE FREDERICK COMPANY, INC.:

Date:	
	Robin E. Abrams, Esquire Vice-President and Director of The Purdue Frederick Company, Inc. and Vice-President and Associate General Counsel of Purdue Pharma L.P. Authorized Corporate Officer for The Purdue Frederick Company, Inc.
Date:	
	Howard M. Shapiro, Esquire Counsel for The Purdue Frederick Company, Inc.
	FOR DEFENDANT MICHAEL FRIEDMAN:
Date:	Michael Friedman, Defendant
Date:	Mark D. Pomerantz, Esquire
	Counsel for Michael Friedman
	FOR DEFENDANT HOWARD R. UDELL:
Date:	Howard R. Udell, Defendant
Date:	Mary Jo White, Esquire Counsel for Howard R. Udell
Date: May 8 200	FOR DEPENDANT PAUL D. GOLDENHEIM:
Date: May 8, 2007	Paul D'Goldenheim Defendant
	Andrew Good, Esquire